Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, September 2008, p. 1429-1435, Vol. 15, No. 9
1071-412X/08/$08.00+0 doi:10.1128/CVI.00169-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Department of Microbiology and Immunology, New York Medical College, Valhalla, New York,1 Biopeptides Corp., Valhalla, New York,2 Falco Biotherapeutics BV, Zernikedreef 9, 2331 CK Leiden, The Netherlands3
Received 13 May 2008/ Returned for modification 23 June 2008/ Accepted 4 July 2008
Mucosal immunization is advantageous over other routes of antigen delivery because it can induce both mucosal and systemic immune responses. Our goal was to develop a mucosal delivery vehicle based on bacteria generally regarded as safe, such as Lactobacillus spp. In this study, we used the Lyme disease mouse model as a proof of concept. We demonstrate that an oral vaccine based on live recombinant Lactobacillus plantarum protects mice from tick-transmitted Borrelia burgdorferi infection. Our method of expressing vaccine antigens in L. plantarum induces both systemic and mucosal immunity after oral administration. This platform technology can be applied to design oral vaccine delivery vehicles against several microbial pathogens.
Published ahead of print on 16 July 2008.
This article has been cited by other articles:
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»